Search Results - "Shinagawa, Atsushi"
-
1
Ixazomib-induced Sweet’s syndrome
Published in International journal of hematology (01-02-2020)Get full text
Journal Article -
2
Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM
Published in Cancer science (01-06-2020)“…In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib and dexamethasone (PVd) significantly improved the progression‐free survival (PFS) and the overall…”
Get full text
Journal Article -
3
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
Published in Japanese journal of clinical oncology (29-06-2023)“…Abstract Background In a Phase 3 international clinical trial (VIALE-C), venetoclax plus low-dose cytarabine improved the response rate and overall survival…”
Get full text
Journal Article -
4
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Published in Japanese journal of clinical oncology (03-01-2022)“…Abstract Background The phase 3 VIALE-A trial (NCT02993523) reported that venetoclax-azacitidine significantly prolonged overall survival compared with…”
Get full text
Journal Article -
5
Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
Published in International journal of hematology (01-04-2018)“…Daratumumab in combination with bortezomib and dexamethasone (DVd) has demonstrated longer progression-free survival than combination of bortezomib and…”
Get full text
Journal Article -
6
TCL1-family negative T-cell prolymphocytic leukemia with rapid progression of extranodal disease despite a normal white blood cell count
Published in Rinshō ketsueki (2024)“…Here we describe the case of a 69-year-old man who was found to have moderate thrombocytopenia and severe splenomegaly during a medical checkup at the age of…”
Get more information
Journal Article -
7
FIP1L1::PDGFRA-positive chronic eosinophilic leukemia showing slowly progressive cardiac impairment
Published in Rinshō ketsueki (2022)“…This report describes a 69-year-old man with eosinophilia that was detected during a medical check-up. A review of his medical history revealed that his…”
Get more information
Journal Article -
8
Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine
Published in Cancer reports (01-01-2024)“…Background Hypomethylating agents, including azacytidine (AZA), are standard therapeutics for patients with high‐risk myelodysplastic syndromes (MDS), a group…”
Get full text
Journal Article -
9
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia
Published in International journal of hematology (01-01-2014)“…Lymphocytosis in response to dasatinib for chronic myelogenous leukemia (CML) may be associated with favorable response. However, it occurs at varying times…”
Get full text
Journal Article -
10
Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
Published in Cancer science (01-05-2016)“…In the FIRST trial (MM‐020), lenalidomide plus low‐dose dexamethasone (Rd) reduced the risk of disease progression or death compared with combination…”
Get full text
Journal Article -
11
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N‐Road study
Published in Cancer medicine (Malden, MA) (01-06-2020)“…For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous…”
Get full text
Journal Article -
12
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
Published in NPJ systems biology and applications (13-10-2022)“…Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR-ABL1 tyrosine kinase. Although ABL1 -specific tyrosine kinase inhibitors…”
Get full text
Journal Article -
13
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia
Published in International journal of hematology (01-05-2011)“…The correlation between imatinib (IM) trough plasma concentration (Cmin) and clinical response was assessed in patients with chronic-phase chronic myeloid…”
Get full text
Journal Article -
14
Quantification of mRNA in Whole Blood by Assessing Recovery of RNA and Efficiency of cDNA Synthesis
Published in Clinical chemistry (Baltimore, Md.) (01-04-2006)“…Current gene expression analysis relies on the assumption that the isolated RNA represents all species of mRNA in proportions equal to those in the original…”
Get full text
Journal Article -
15
Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia
Published in Case reports in hematology (01-01-2019)“…A 38-year-old woman with aggressive clinical course of chronic lymphocytic leukemia (CLL) was treated with 8 courses of R-CHOP. Clinical remission was…”
Get full text
Journal Article -
16
Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase
Published in Journal of Clinical and Experimental Hematopathology (2014)“…Dasatinib is a BCR-ABL kinase inhibitor with improved potency compared with imatinib, for which efficacy and safety in imatinib-resistant and…”
Get full text
Journal Article -
17
ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)
Published in Modern pathology (01-08-2003)“…Pathological features and genomic basis of a rare case of ALK+, CD30−, CD20− large B-cell lymphoma were analyzed. A 36-year-old Japanese female was admitted…”
Get full text
Journal Article -
18
Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine
Published in Rinshō ketsueki (2017)“…A 66-year-old male underwent prednisolone (PSL) therapy of 13 mg/day for rheumatoid arthritis (RA). Antiphospholipid antibody syndrome, neutrophilic dermatosis…”
Get more information
Journal Article -
19
Ex Vivo Induction of mRNA in Human Whole Blood as a New Platform of Drug and Dietary Supplement Development
Published in Pharmaceutical research (01-05-2008)“…Purpose We introduced a new concept of ex vivo gene expression analysis (Mitsuhashi, Clin Chem 53:148–149, 2007), where drug action was simulated under…”
Get full text
Journal Article -
20
A CASE OF GRANULOCYTIC SARCOMA IN THE BILATERAL URETER
Published in Nippon Hinyokika Gakkai zasshi (20-07-2015)“…A 61-year-old female presented with the complaints of fever and left back pain. She had previously undergone bone marrow transplantation for acute myeloid…”
Get more information
Journal Article